Story · Medicine & Biotech

Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough?

1 outlet · first reported by OncoDaily on

Gilberto Lopes, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared on LinkedIn: “Ivonescimab, the FDA, and a difficult question in oncology: When is progression-free (OncoDaily)

Coverage, in order

  1. OncoDaily obscure opinion
    Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough?

    Gilberto Lopes, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared on LinkedIn: “Ivonescimab, the FDA, and a difficult question in oncology: When is progression-free

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.